SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (“Second Sight” or “the Company”) (Nasdaq:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced the publication of a positive 3-year FLORA study in the Australian journal Clinical And Experimental Optometry for the Argus® II Retinal Prosthesis System (“Argus II”). The Functional Low-Vision Observer Rated Assessment (FLORA), a multi-part
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and …
MIAMI — An anti-complement C5 therapy had no different effect on geographic atrophy lesion size than sham therapy, according to a presentation at Angiogenesis, Exudation, and Degeneration 2016.“No efficacy was observed,” Parisa Zamiri, MD, PhD, said of the treatment drug LFG316 in her presentation on the drug’s 12-month safety and efficacy results.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/rqtrd3/retinoblastomaglo) has announced the addition of the “Retinoblastoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016” report to thei…
Sequential glaucoma drainage device implantation and transscleral diode cyclophotocoagulation both reduce IOP after failure of a primary drainage device, but cyclophotocoagulation may carry less risk for adverse events, according to a study.The retrosp…
(MedPage Today) — Signs of AMD regressed in small trial